Effects of tepary bean (Phaseolus acutifolius) protease inhibitor and Semipure lectin fractions on cancer cells

Nutrition and Cancer

Volumn 64, Issue 8, 2012, Pages 1269-1278

  García Gasca, Teresa ^a   García Cruz, Marlen ^b   Hernandez Rivera, Elisa ^a   Josue Lopez Matinez ^a   Castañeda Cuevas, Ana L ^a   Yllescas Gasca, Lorena ^a   Mendiola Olaya, Elizabeth ^b   Castro Guilĺen, Jośe L ^b   Blanco Labra, Alejandro ^b  

^a UNIVERSIDAD AUTÓNOMA DE QUERÉTARO   (Mexico)

^b DEPARTAMENTO DE FÍSICA   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

BOWMAN BIRK INHIBITOR; GELATINASE B; PLANT LECTIN; TEPARY BEAN PROTEASE INHIBITOR; TEPARY LECTIN FRACTION; TEPARY LECTIN RICH FRACTION; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER GROWTH; CELL ADHESION; CELL INVASION; CELL TRANSFORMATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG PURIFICATION; ENZYME ACTIVITY; ENZYME DEGRADATION; ENZYME REPRESSION; EXTRACELLULAR MATRIX; FEMALE; FIBROBLAST; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; NONHUMAN; PLANT SEED; PROTEIN ANALYSIS; PROTEINASE INHIBITION; SOYBEAN; TEPARY BEAN;

3T3 CELLS; ANIMALS; CACO-2 CELLS; CELL ADHESION; CELL LINE, TUMOR; CELL PROLIFERATION; EXTRACELLULAR MATRIX; HELA CELLS; HUMANS; LECTINS; MCF-7 CELLS; MICE; NEOPLASM INVASIVENESS; PHASEOLUS; PROTEASE INHIBITORS; SEEDS;

EID: 84873684012     PISSN: 01635581     EISSN: 15327914     Source Type: Journal    
DOI: 10.1080/01635581.2012.722246     Document Type: Article

References (59)

1. DeClerck YA, Mercurio AM, Snack MS, Chapman HA, Zutter MM, et al.: Proteases, extracellular matrix, and cancer. Am. J. Path 164, 1131-1139, 2004.
2. Yavelow J, Findlay HT, Kennedy AR, and Troll W: Bowman-Birk soybean protease inhibitor as an antiarcinogen. Cancer Res 43(Suppl.), 2454S-2459S, 1983.
3. Kennedy AR, Randner BS, and Nagasawa H: Protease inhibitors reduce the frequency of spontaneous chromosome abnormalities in cells from patients with Bloom syndrome. Proc Natl Acad Sci (USA) 81, 1827-1830, 1984.
4. Kennedy AR: Cancer prevention by protease inhibitors. Prev Med 22, 796-811, 1993.
5. Gueven N, Dittman K, Mayer C, and Rodemann HP: The radioprotective potential of the Bowman-Birk protease inhibitor is independent of its secondary structure. Cancer Lett 125, 77-82, 1998.
6. Kennedy AR: Chemopreventive agents: protease inhibitors. Pharmacol Ther 78, 167-209, 1998.
7. Kennedy AR: The Bowman-Birk inhibitor from soybeans as an anticarcinogenic agent. Am J Clin Nutr 68(Suppl.), 1406S-1412S, 1998.
8. Du X, Beloussow K, and Shen W: Bowman-Birk protease inhibitor and its palmitic acid conjugate prevent 7, 12 dimethylbenz(a)anthracene induced transformation in culture mouse mammary glands. Cancer Lett 164, 135-141, 2001.
9. Witschi H and Espiritu I: Development of tobacco smoke-induced lung tumors in mice fed Bowman-Birk protease inhibitor concentrate (BBIC). Cancer Lett 183, 141-146, 2002.
10. Kashiwagi K, Virgona N, Yamada J, Sato A, Ota M, et al.: Bowman-Birk protease inhibitor from soybeans enhances cisplatin-induced cytotoxicity in human mesothelioma cells. Exp Ther Med 2, 719-724, 2011.
11. Yavelow J, Collins M, Birk Y, Troll W, and Kennedy AR: Nanomolar concentration of Bowman-Birk soybean protease inhibitor suppresses x-rayinduced transformation in vitro. Proc Natl Acad Sci (USA) 86, 9871-9875, 1985.
12. Lippman SM and Matrisian LM: Protease inhibitors in oral carcinogenesis and chemoprevention. Clin Cancer Res 6, 4599-4603, 2000.
13. USA patent number 7696173: Compositions Comprising Bowman-Birk Protease Inhibitors and Variants Thereof. Available online: http://www.patentgenius.com/ patent/7696173.html
14. Tareq A-A: . Plant Lectins. Poisonous Plants Homepage: Animal Science at Cornell University. Available online: http://www.ansci.cornell. edu/plants/toxicagents/lectins.html
15. Kiss R, Camby I, Duckworth D, De-Decker R, and Salmon I: In vitro influence of Phaseolus vulgaris, Griffonia simplicifolia, Concavalin A, wheat germ and peanut agglutinins on HCT-15, LoVo and SW 837 human colorrectal cancer cell growth. Gut 40, 253-261, 1997.
16. González de Mejiá E and Prisecaru VI: . Lectins as Bioactive Plant Proteins: A Potential in Cancer Treatment. Crit Rev Food Sci Nutr 45, 425-445, 2005.
17. Ferriz-Martinez RA, Torres-Arteaga IC, Blanco-Labra A, and Garcia-Gasca T: The role of plant lectins in cancer treatment. In: The New Approaches in the Treatment of Cancer, Mejia C and Navarro S (eds.). Nova Science Publishers, NY, USA, 2010, pp. 71-89.
18. Lyu S, Choi SH, Park WB, and Kim W: Involvement of caspase-3 in apoptosis induced by Viscum album var. coloratum agglutinin in HL-60 cells. Biosci Biothecnol. Biochem 65, 534-541, 2001.
19. Pryme IF and Bardocz S: Anti-cancer therapy: Diversion of polyamines in the gut. Eur J Gastroenterol Hepatol 13, 1041-1046, 2001.
20. Lyu S, Choi SH, and Park WB: Korean mistletoe lectin-induced apoptosis in hepatocarcinoma cells is associated with inhibition of telomerase via mitochondrial controlled pathway independent of p-53. Arch Pharm Res 25, 93-101, 2002.
21. Campos J, Martínez-Gallardo N, Mendiola-Olaya E, and Blanco-Labra A: Purification and partial characterization of a proteinase inhibitor from Tepary bean (Phaseolus acutifolius) seeds. J Food Biochem 21, 203-218, 1997.
22. García-Gasca T, Salazar-Olivo LA, Mendiola-Olaya E, and Blanco-Labra A: The effects of a protease inhibitor fraction from Tepary bean (Phaseolus acutifolius) on in vitro cell proliferation and cell adhesion of transformed cells. Toxicol In Vitro 16, 229-233, 2002.
23. Bradford M: Arapid and sensitive method for the quantitation ofmicrogram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72, 248-254, 1976.
24. Jaffé W: Hemagglutinins (lectins). In: Toxic Constituents of Plant Foodstuffs. New York: Academic Press, 1980, pp. 73-102.
25. Schwertz G and Takenaka Y: Spectrophotometric determination of trypsin and chymotrypsins activity. Biochim Biophys Acta 16, 571-575, 1955.
26. Gerard C: Purification of glycoproteins. In: Guide to Protein Purification, Deutscher MP (ed.). San Diego, CA: Academic Press, 1990, pp. 535-536.
27. Laemmli UK: Cleavage of structural proteins during the assembly of the head bacteriophage T4. Nature 227, 680-685, 1970.
28. Garciá-Gasca T, Paz-González V, Moncada-Álvarez M, Blanco-Labra A, and Salazar-Olivo L: Colorimetric quantitation of in vitro cell density using carmine a chromosome-specific stain. Toxicol In Vitro 16, 573-579, 2002.
29. Ignotz RA and Messague J: Transforming growth factor β stimulates the expression of fibronectin and collagen and their incorporation into the extracellular matrix. J Biol Chem 261, 4337-4345, 1986.
30. Hawkes SP, Li H, and Taniguchi GT: Zymography and reverse zymography for detecting MMPs and TIMPs. In: Matrix Metalloproteinase Protocols. Methods in Molecular Biology (2nd ed.), Clark IM (ed.), and Young DA and Rowan AD (consulting eds.). New York: Humana Press, 2010, pp. 257-269.
31. Pusztai A, Watt WB, and Stewart JC: Erithro- and lymphoaglglutinins of Phaseolus acutifolius. Phytochem 26, 1009-1013, 1987.
32. Pratt RC, Singh NK, Shade RE, Murdock LL, and Bressan RA: Isolation and partial characterization of a seed lectin from tepary bean that delays bruchid beetle development. Plant Physiol 93, 1453-1459, 1990.
33. Vargas-Albores F, de la Fuente G, Agundis C, and Córdoba F: Purification and characterization of a lectin from Phaseolus acutifolius var. latifolius. Prep Biochem 17, 379-396, 1987.
34. Reynoso-Camacho R, Gonzalez de Mejia E, and Loarca-Piña G: Purification and acute toxicity of a lectin extracted from Tepary bean (Phaseolus acutifolius). Food Chem Toxicol 41, 21-27, 2003.
35. Castillo-Villanueva A, Caballero-Ortega H, Abdullaev-Jafarova F, Ganfias Y, Jiménez-Martínez M, et al.: Lectin from Phaseolus acutifolius var. escumite: chemical characterization, sugar specificity, and effect on human T-lymphocytes. J Agric Food Chem 55, 5781-5787, 2007.
36. de Mejía EG, Hankin C, Paredes-López O, and Shannon L: The lectins and lectin-like proteins of Tepary beans (Phaseolus acutifolius) and Teparycommon bean (Phaseolus vulgaris) hybrids. J Food Biochem 14, 117-126, 1990.
37. Sharon N: Lectin-carbohidrate complexes of plants and animals: an atomic view. TIBS 18, 221-226, 1996.
38. Sharon N and Lis H: History of lectins: from hemagglutinins to biological recognition molecules. Glycobiology 14, 53R-62R, 2004.
39. Won-Ho K, Won BP, Bin G, and Myeong HJ: Critical role of reactive oxygen species and mitochondrial membrane potential in Korean mistletoe lectin-induced apoptosis in human hepatocarcinoma cells. Mol Pharmacol 66, 1383-1396, 2004.
40. Petrossian K, Banner LR, and Oppenheimer SB: Lectin binding and effects in culture on human cancer and non-cancer cell lines: Examination of issues of interest in drug design strategies. Acta Histochem 109, 491-500, 2007.
41. Valadez-Vega C, Guzmán-Partida AM, Soto-Cordova FJ, Álvarez-Manilla G, Morales-González JA, et al.: Purification, biochemical characterization, and bioactive properties of a lectin purified from the seeds of white tepary bean (Phaseolus acutifolius variety Latifolius). Molecules 16, 2561-2582, 2011.
42. Valadez-Vega C, Alvarez-Manilla G, Riverón-Negrete L, García-Carrancá A, Morales-González JA, et al.: Detection of cytotoxic activity of lectin on human colon adenocarcinoma (Sw480) and epithelial cervical carcinoma (C33-A). Molecules 16, 2107-2118, 2011.
43. Benaud CM, Oberst M, Dickson RB, and Lin CY: Deregulated activation of matriptase in breast cancer cells. Clin Exp Metastasis 19, 639-649, 2002.
44. Uhland K: Matriptase and its putative role in cancer. Cell Mol Life Sci 63, 2968-2978, 2006.
45. Pandey R, Patil N, and Rao M: Proteases and protease inhibitors: implications in antitumorogenesis and drug development. Int J Hum Genet 7, 67-82, 2007.
46. Castro-Guillén JL, Garcia-Gasca T, and Blanco-Labra A: Protease inhibitors as anticancer agents. In: The New Approaches in the Treatment of Cancer, Mejia C and Navarro S (eds.). Nova Science Publishers, Inc., NY, USA, 2010, pp. 91-124.
47. Ghosh S, Brown R, Jones JC, Ellerbroek SM, and Stack MS: Urinarytype plasminogen activator (uPA) expression and uPA receptor localization are regulated by α3β1 integrin in oral keratinocytes. J Biol Chem 275, 23869-23876, 2000.
48. Ray J, and Stetler-Stevenson W: Gelatinase A activity directly modulates melanoma cell adhesion and spreading. EMBO J. 14, 908-917, 1995.
49. Woessner JF Jr: . The matrix metalloproteinase family. In: Matrix Metalloproteinases, Parks WC and Mecham RP (eds.). San Diego, CA: Academic Press, 1998, Pp. 1-13.
50. Bodey B, Bodey JB, Siegel SE, and Kaiser HF: Matrix metalloproteinase expression in malignant melanomas: tumor-extracellular matrix interactions in invasion and metastasis. In Vivo 15, 57-64, 2001.
51. Riikonen T, Westermarck J, Koivisto L, Broberg A, Kahari VM, et al.: Integrin α2β1 is a positive regulator of collagenase (MMP-1) and collagenα1 (I) gene expression. J Biol Chem 270, 13548-13552, 1995.
52. Koblinski JE, Ahram M, and Sloana BF: Unraveling the role of proteases in cancer. Clin Chim Acta 291, 113-135, 2000.
53. Kleiner DE and Stetler-Stevenson WG: Matrix metalloproteinases and metastasis. Cancer Chemother. Pharmacol 43(Suppl.), S42-S51, 1999.
54. Yin S, Lockett J, Meng Y, Biliran H Jr, Blouse GE, et al.: Maspin retards cell detachment via a novel interaction with the urokinase-type plasminogen activator/urokinase-type plasminogen activator receptor system. Cancer Res 66, 4173-4181, 2006.
55. Moy LY and Billings PC: A proteolytic activity in a human breast cancer cell line which is inhibited by the anticarcinogenic Bowman-Birk protease inhibitor. Cancer Lett 85, 205-210, 1994.
56. Mazzieri R, Masiero L, Zanetta L, Monea S, Onisto M; et al: Control of type IV collagenase activity by components of the urokinase-plasmin system: a regulatory mechanism with cell-bound reactants. EMBO J 16, 2319-2332, 1997.
57. Ware JH, Wan XS, Rubin H, Schechter NM, and Kennedy AR: Soybean Bowman-Birk protease inhibitor is a highly effective inhibitor of human mast cell chymase. Arch Biochem Biophys 344, 133-138, 1997.
58. Chambers AF and Matrisian LM: Changing views of the role of matrix metalloproteinases in metastasis. J. Natl. Cancer Inst 89, 1260-1270, 1997.
59. Kennedy AR and Wan XS: Effects of the Bowman-Birk inhibitor on growth, invasion, and clonogenic survival of human prostate epithelial cells and prostate cancer cells. Prostate 50, 125-133, 2002.